Brexucabtagene autoleucel
Phase 2Cell therapy
GileadBrexucabtagene autoleucel is a cell therapy that works as a CD19 CAR-T.[2] It is being investigated across 4 indications, with its most advanced program in Phase 2.[1]
Brexucabtagene autoleucel is one of 113 cell therapy programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 2.
4
Indications
11
Total Trials
4
Active Trials
112
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
408 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Cellcept
RochePhase 3
Arranon
NovartisPhase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Zinecard
PfizerPhase 3
Leukine
SanofiPhase 3
Busulfex
Akero TherapeuticsPhase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Mantle Cell Lymphoma2 trials
Acute Lymphoblastic Leukemia2 trials
Treatment1 trial
4 more indications
B-cell Malignancies1 trial
Relapsed/Refractory B-cell Malignancies1 trial
Randomized1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Brexucabtagene autoleucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]